Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 1/20 | 0.73 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.47 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.45 |
| ▸ | EGFR | P00533 | 7/20 | 0.45 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | ERBB3 | P21860 | 5/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3220007 | 0.82 | S1PR1 (0.52) | KMOEGFRMEN1KMT2ANPC1 | |
| SCHEMBL14800006 | 0.81 | KMO (0.51) | KMOGRM4NOTUMMEN1KMT2A | |
| SCHEMBL3225993 | 0.80 | MEN1 (0.57) | KMOEGFRMEN1KMT2AMAPT | |
| SCHEMBL31691382 | 0.76 | MEN1 (0.57) | KMOEGFRMEN1KMT2ANPC1 | |
| SCHEMBL1938700 | 0.75 | KMO (0.69) | KMONOTUM | |
| SCHEMBL14800447 | 0.74 | KMO (0.52) | KMONOTUMEGFRMEN1KMT2A | |
| SCHEMBL12484796 | 0.74 | MEN1 (0.46) | KMOEGFRFGFR1MEN1KMT2A | |
| SCHEMBL27322724 | 0.72 | KMO (0.57) | KMOEGFRMEN1KMT2ANPC1 | |
| SCHEMBL4874060 | 0.72 | NPC1 (0.57) | EGFRMEN1KMT2AMAPTNPC1 | |
| SCHEMBL4000055 | 0.72 | MAPK1 (0.48) | MAPTCYP1A2CYP3A4CYP2C19ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130331370-A1 | CERTAIN KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | WITYAK JOHN (US) | 2013-12-12 | — | — | US | claimed |
| US-20110183957-A1 | CERTAIN KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | CHDI FOUNDATION, INC. | 2011-07-28 | — | — | US | claimed |
| EP-2331095-A1 | CERTAIN KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | CHDI, Inc. (US) | 2011-06-15 | — | — | EP | claimed |
| WO-2010017179-A1 | CERTAIN KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | CHDI, INC. (US) | 2010-02-11 | — | — | WO | claimed |
| US-9145373-B2 | Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | CHDI FOUNDATION, INC. (US) | 2015-09-29 | — | — | US | disclosed |
| EP-2331095-B1 | CERTAIN KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | CHDI FOUNDATION INC (US) | 2014-10-15 | — | — | EP | disclosed |
| US-20130331370-A1 | CERTAIN KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | WITYAK JOHN (US) | 2013-12-12 | — | — | US | disclosed |
| US-8536186-B2 | Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | CHDI FOUNDATION, INC. (US) | 2013-09-17 | — | — | US | disclosed |
| US-20110183957-A1 | CERTAIN KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | CHDI FOUNDATION, INC. | 2011-07-28 | — | — | US | disclosed |
| EP-2331095-A1 | CERTAIN KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | CHDI, Inc. (US) | 2011-06-15 | — | — | EP | disclosed |
| WO-2010017179-A1 | CERTAIN KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | CHDI, INC. (US) | 2010-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110183957-A1 | CERTAIN KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | KMO, KYNU, MAOA | KMO 1/4885GRM4 331/4885NOTUM 665/4885 |
| US-20130331370-A1 | CERTAIN KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | KMO, KYNU, MAOA | KMO 1/4885GRM4 331/4885NOTUM 665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.